Ecolab (ECL)
NYSEMaterialsSpecialty ChemicalsSnapshot 2026-07-07
$283.15-0.20%
Close 2026-07-07 · 1-day change
Reading ECL? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ECL free→NYSEMaterialsSpecialty ChemicalsSnapshot 2026-07-07
Reading ECL? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ECL free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a focus on maintaining earnings per share (EPS) growth. The current thesis state is intact, supported by recent strong financial performance, but management execution remains volatile.
The valuation is considered expensive compared to peers, with a durable premium. The market seems to expect continued strong performance, but there is a notable expectations gap.
Fundamentals may show mixed results as management aims to maintain EPS growth and manage capital allocation. Recent changes indicate a mild favorable shift, but the company has a history of missing targets.
The long-term thesis hinges on management's ability to meet EPS targets and the performance of sector bellwethers like LIN, SHW, and APD. Any guidance cuts or misses from these companies could negatively impact ECL.
Over the next 1 to 3 years, ECL's performance will depend on execution and sector dynamics. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. Ecolab raised $5 billion to invest in AI data center cooling. This investment aligns with their capital allocation strategy. There are no new threats to the thesis.
as of 2026-07-07
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: This range reflects how well Ecolab manages rising commodity costs and pricing. Meeting this target shows strong earnings growth.
Confirms:Adjusted diluted EPS reported in Q2 2026 falls within the $2.02 to $2.12 range.
Disproves:Adjusted diluted EPS reported in Q2 2026 is below $2.02.
Why it matters: Rising commodity costs could pressure margins. How Ecolab manages these costs will impact earnings.
Confirms:Commodity costs increase high single digits as expected in Q2 2026.
Disproves:Commodity costs do not rise as expected or stabilize.
Why it matters: Rising costs will affect margins and pricing strategies. This will impact overall profits.
Confirms:Commodity costs are rising in high single digits. This negatively affects gross margins.
Disproves:If commodity costs stay the same or go down, margins might get better.
Why it matters: Hitting EPS guidance shows Ecolab can keep growing. This is important for investor trust.
Confirms:Q2 2026 EPS reported between $2.02 and $2.12.
Disproves:Q2 2026 EPS falls below $2.02.
Why it matters: This acquisition is key for Ecolab's growth in the data center cooling market. It could boost sales growth significantly.
Confirms:The acquisition will close in Q3 2026 as planned. There are no regulatory delays.
Disproves:The acquisition is delayed or blocked. This is due to regulatory issues.
Why it matters: Improved revenue growth would signal recovery in Ecolab's performance. This is vital for long-term growth.
Confirms:Q2 2026 revenue growth exceeds 1% year over year.
Disproves:Q2 2026 revenue growth remains below 1% year over year.
Why it matters: Positive cash flow is key for capital allocation and growth. It shows financial health.
Confirms:Cash flow from operations was positive. It was negative $769.2M in 2025-Q4.
Disproves:Cash flow from operations is still negative.
Why it matters: A good buyback can raise stock price. It shows management believes in the company.
Confirms:Stock price increases after the announcement of the $1.2 billion share buyback.
Disproves:Stock price goes down even after the buyback announcement.
Why it matters: Strong growth in Life Sciences helps Ecolab's sales and pricing.
Confirms:Life Sciences organic sales growth above 11% in Q2.
Disproves:Life Sciences organic sales growth is below 8%. This shows possible weakness.
Why it matters: Strong growth in this segment is crucial for Ecolab's overall performance. It shows demand for their advanced solutions.
Confirms:Organic sales growth in Global High-Tech will be over 20% in the next quarters.
Disproves:Organic sales growth in Global High-Tech falls below 20%.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.